News:
11/20/2013 - MSM Protein Technologies Secures Second Pre-Clinical Debiopharm Milestone04/10/2013 - MSM satisfies first Debiopharm milestone
03/25/2013 - MSM is pleased to announce the appointment of Dr. Edward Kislauskis to its Scientific Advisory Board
11/03/2012 - Andrea Corcoran appointed as CFO and in-house counsel
12/15/2011 - MSM Protein Press Release
05/09/2011 - Anti-G-protein-coupled receptor antibodies successfully generated in collaboration with MSM Protein Technologies (Chiome Press Release)
05/25/2010 - MSM Protein Technologies Announces the Appointment of Dr. Christopher Hentschel to the Board of Directors
08/20/2009 - Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
07/30/2009 - Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface Receptors
11/10/2008 - MSM Protein Technologies secures funding from Cystic Fibrosis Foundation
10/17/2006 - MSM Protein Technologies Inc. forms drug discovery collaboration with U.K.-based Cambridge Antibody Technology
PDF Downloads:
- 11/20/2013 - MSM Protein Technologies Secures Second Pre-Clinical Debiopharm Milestone
- 4/10/2013 - MSM satisfies first Debiopharm milestone
- 3/25/13 - MSM is pleased to announce the appointment of Dr. Edward Kislauskis to its Scientific Advisory Board
- 11/3/2012 - Andrea Corcoran appointed as CFO and in-house counsel
- 12/15/2011 - MSM Protein Press Release
- 5/25/2010 - Appointment of Dr. Christopher Hentschel to the Board of Directors
- 8/20/2009 - Debiopharm and MSM Protein Technologies
- 7/30/2009 - Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface Receptors
- 11/10/2008 - MSM Protein Technologies secures funding from Cystic Fibrosis Foundation
- 10/17/2006 - MSM Protein Technologies Inc. forms drug discovery collaboration with U.K.-based Cambridge Antibody Technology
